Skip to Main Content

Paper Details

Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903).
Clin Cancer Res
22
2021
Author NameAffiliation
Jyoti MalhotraRutgers Cancer Institute of New Jersey
Pasi A J??nneDana-Farber Cancer Institute
  • 1 - 2

Datasets

Release 1.2